Share on StockTwits

Equities researchers at Roth Capital upped their target price on shares of BioDelivery Sciences International (NASDAQ:BDSI) to $20.00 in a research report issued on Friday. Roth Capital’s price objective suggests a potential upside of 48.37% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. BioDelivery Sciences International presently has a consensus rating of “Buy” and an average price target of $20.50.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at 13.48 on Friday. BioDelivery Sciences International has a 1-year low of $4.16 and a 1-year high of $14.44. The stock’s 50-day moving average is $12.72 and its 200-day moving average is $9.85. The company’s market cap is $653.0 million.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.